Premium
Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia
Author(s) -
Crow Andrew R.,
Song Seng,
Siragam Vinayakumar,
Lazarus Alan H.
Publication year - 2006
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20980
Subject(s) - medicine , immunology , antibody , immune system , thrombocytopenic purpura , autoantibody , immunotherapy
Intravenous immunoglobulin (IVIG) is currently used to treat a multitude of autoimmune disorders including immune thrombocytopenic purpura (ITP), yet the mechanism of action of IVIG remains unresolved. Using a murine model of ITP in which IVIG functions therapeutically, our laboratory has addressed such theories as blockade/inhibition of the mononuclear phagocytic system, cytokine regulation, and neutralization of pathogenic autoantibodies mediated by anti‐idiotypic antibodies, and these findings will be discussed herein. We have also demonstrated that soluble immune complexes can completely recapitulate the therapeutic effects of IVIG in ITP, and recent work from us has identified activating Fcγ receptors on CD11c + dendritic cells as the relevant molecular target of IVIG in the acute resolution of murine immune thrombocytopenia. This and other work to devise antibody‐based IVIG alternative therapies will also be addressed. Pediatr Blood Cancer 2006;47:710–713. © 2006 Wiley‐Liss, Inc.